Daprodustat is potential treatment for anaemia with CKD.
Compelling data from FULFIL study puts GSK in pole position
How pharma can move on from the recent controversies around pricing is one of the industry’s biggest issues.
Shingrix has blockbuster potential, according to analysts.
Collaboration focuses on cancer epigenetics.
Actions of Chinese subsidiaries violated US bribery laws, says SEC.